Oral Administration of Hyperimmune Eggs Induces Mucosal IgA Responses, Anti-Idiotypic Antibodies, and HIV-1 Neutralizing Activity: A Proof-of-Concept Preclinical Study

Abstract

The development of effective mucosal vaccination strategies against human immunodeficiency virus type 1 (HIV-1) remains a major challenge. This study investigated whether oral administration of hyperimmune anti-HIV-1 gp120 immunoglobulin Y (IgY) could induce mucosal and systemic immune responses in outbred felines through an anti-idiotypic network mechanism. A controlled immunization study involving 42 cats (18 immunized and 24 controls) was conducted to evaluate mucosal anti-gp120 IgA responses. In addition, a proof-of-concept cohort was used to investigate anti-idiotypic antibody (Ab-3) induction, competitive inhibition, and HIV-1 neutralization. Anti-gp120 IgA antibodies were detected in saliva from immunized animals but were absent or present at low levels in controls, indicating activation of mucosal immunity. All immunized cats developed detectable Ab-3 responses against HIV-1 gp120. Competitive inhibition assays demonstrated specific in hibition of gp120-related interactions, supporting the presence of biologically relevant anti-idiotypic antibodies. Furthermore, sera from immunized animals significantly reduced HIV-1 infectivity in a TZM-bl luciferase-based neutralization assay, with viral inhibition exceeding 60% at selected dilutions. Collectively, these findings demonstrate that oral administration of hyperimmune anti-gp120 IgY can induce mucosal IgA responses, systemic anti-idiotypic antibodies, and functional HIV-1 neutralizing activity. This preclinical proof-of-concept study supports further investigation of IgY-based oral immunization as a potential platform for HIV vaccine development. However, the Ab3, competitive inhibition assay using Ab3, and HIV-1 neutralization studies should be regarded as exploratory proof-of-concept investigations designed to establish biological plausibility rather than definitive efficacy.